A Randomized Comparison of 2 Different Drug-Coated Balloons for In-Stent Restenosis
JACC: Cardiovascular Interventions · 2023
DOI: 10.1016/j.jcin.2022.12.018 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2023. Verfasst von Shengwen Liu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Fu Wai Hospital, National Center for Cardiovascular Diseases of China, Beijing, China. Hauptthemen laut MEDLINE: Angioplasty, Balloon, Coronary, Coronary Restenosis, Drug-Eluting Stents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Although use of drug-coated balloons (DCB) is a promising technique, little is known about the clinical efficacy of the Dissolve DCB in drug-eluting stent (DES) in-stent restenosis (ISR). OBJECTIVES: This study sought to evaluate the efficacy and safety of the Dissolve DCB in patients with DES ISR. METHODS: This was a prospective, multicenter, randomized, noninferiority trial comparing Dissolve DCB with SeQuent Please DCB in patients with DES ISR. Angiographic and clinical follow-up was planned at 9 months in all patients. The primary endpoint was 9-month in-segment late loss. RESULTS: A total of 260 patients with ISR from 10 Chinese sites were included (Dissolve DCB, n = 128; SeQuent Please DCB, n = 132). Nine-month in-segment late loss was 0.50 ± 0.06 mm with Dissolve DCB vs 0.47 ± 0.07 mm with SeQuent Please DCB; the 1-sided 97.5% upper confidence limit of the difference was 0.18 mm (P for noninferiority = 0.03). Rates of target lesion failure and binary restenosis were numerical higher in the Dissolve DCB cohort compared with the SeQuent Please DCB cohort at 9 months (17.5% vs 10.7%; P = 0.12; 23.4% vs 16.4%; P = 0.19, respectively). At 9 months, major adverse cardiac and cerebrovascular events occurred in 36 patients (28.3%) vs 30 patients (22.9%) in the Dissolve DCB and SeQuent Please DCB groups, respectively. CONCLUSIONS: In this head-to-head randomized trial, the Dissolve DCB was noninferior to the SeQuent Please DCB for 9-month in-segment late loss. However, Dissolve DCB with its numerical increase in target lesion failure and binary restenosis warrants assessment in larger clinical trials (A Safety and Efficacy Study of Dissolve™ in Treatment of Coronary In-Stent Restenosis; NCT03373695).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Fu Wai Hospital, National Center for Cardiovascular Diseases of China, Beijing, China.
- Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
- Department of Cardiology, Peking Union Medical College Hospital, Beijing, China.
- Department of Cardiology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
- Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Department of Cardiology, Sir Run Run Shaw, Zhejiang University School of Medicine, Zhejiang, China.
Zitieren
APA
Liu, S., Zhou, Y., Shen, Z., Chen, H., Qiu, C., Fu, G., Li, H., Yu, Z., Zeng, Q., Li, Z., Li, W., Qiao, S., & Dissolve ISR Investigators (2023). A Randomized Comparison of 2 Different Drug-Coated Balloons for In-Stent Restenosis. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2022.12.018
Vancouver
Liu S, Zhou Y, Shen Z, Chen H, Qiu C, Fu G, et al. A Randomized Comparison of 2 Different Drug-Coated Balloons for In-Stent Restenosis. JACC: Cardiovascular Interventions. 2023. doi:10.1016/j.jcin.2022.12.018
BibTeX
@article{Liu2023,
author = {Liu, Shengwen and Zhou, Yujie and Shen, Zhujun and Chen, Hui and Qiu, Chunguang and Fu, Guosheng and Li, Hui and Yu, Zaixin and Zeng, Qiutang and Li, Zhanquan and Li, Wei and Qiao, Shubin and Dissolve ISR Investigators, Dissolve ISR Investigators},
title = {A Randomized Comparison of 2 Different Drug-Coated Balloons for In-Stent Restenosis},
journal = {JACC: Cardiovascular Interventions},
year = {2023},
doi = {10.1016/j.jcin.2022.12.018}
}
EUVIMED